Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma

Chinese Journal of Cancer

Volumn 28, Issue 2, 2009, Pages 146-149

  Xia, Yi ^a   Li, Zhi Ming ^a   Shi, Yan Xia ^a   Xia, Zhong Jun ^a   Jiang, Wen Qi ^a   Huang, Hui Qiang ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Chemotherapy; Efficacy; Germinal center B cell like; Immunohistichemistry; Lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ASSESSMENT; DRUG EFFICACY; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DNA-BINDING PROTEINS; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEPRILYSIN; PREDNISONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; VESICULAR TRANSPORT PROTEINS; VINCRISTINE; YOUNG ADULT;

EID: 70349632467     PISSN: 1000467X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J]. Nature, 2000,403(6769):503-511.
2. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma [J]. N Engl J Med, 2002,346(25):1937-1947.
3. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning [J]. Nat Med, 2002,8(1):68-74.
4. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes [J]. N Engl J Med, 2004,350(18):1828-1837.
5. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma [J]. N Engl J Med, 2002,346(4):235-242.
6. Pfreundschuh M, Osterborg A, Pettengeu R, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group [J]. Lancet Oncol, 2006,7(5):379-391.
7. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma [J]. J Clin Oncol, 2007,25(5):579-586.
8. Hans CP, Weisenburger DD, Greiner TC, et a1. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray [J]. Blood, 2004,103(1):275-282.
9. A predictive model for aggressive non-Hodgkin's lymphoma. The International non-Hodgkin's Lymphoma Prognostic Factors Project [J]. N Engl J Med, 1993,329(14):987-994.
10. Chang CC, MeClintock S, Cleveland RP, et al. Immunohistochemistry expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma [J]. Am J Surg Pathol, 2004,28(4):464-470.
11. Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma [J]. Blood, 2003,101(1):78-84.
12. Ye ZY, Cao YB, Lin TY, et al. Correlation between immunophenotyping of diffuse large B-cell lymphoma and prognosis [J]. Zhonghua Bing Li Xue Za Zhi, 2007,36(10):654-659.
13. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma [J]. Blood, 1996,87(1):265-272.
14. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma [J]. Blood, 1997,90(1):244-251.
15. Rantanen S, Monni O, Joensuu H, et al. Causes and consequences of BCL-2 overexpression in diffuse large B-cell lymphoma [J]. Leuk Lymphoma, 2001,42(5):1089-1098.
16. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) [J]. Blood, 2003,101(11):4279-4284.
17. Kusumoto S, Kobayashi Y, Sekiguchi N, et al. Diffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a "non-germinal center phenotype" [J]. Am J Surg Pathol, 2005,29(8):1067-1073.
18. Jiang HY, Li HL, Hu H, et al. t (14:18) translocation in diffuse large B-cell lymphoma and detection of bcl-2 gene amplification [J]. Zhonghua Bing Li Xue Za Zhi, 2007,36 (2):84-89.